Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Indian J Dermatol ; 68(4): 487, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37822401

RESUMO

Background: The appearance of the scalp and hair is very important aesthetically regardless of age or sex. Although there are many drugs and treatment methods for scalp problems and hair loss, the treatment response is still insufficient. Aims and Objectives: To evaluate the efficacy of low-level light therapy in a helmet-like device. Materials and Methods: This study was designed as a 24-week trial with 50 participants. All participants used a helmet-shaped device emitting 630-690, 820-880, and 910-970 nm light wavelengths, for 20 minutes, daily for 24 weeks. A phototrichogram for hair density and thickness, Global Aesthetic Improvement Scale score, erythema index, and sebum secretions of the scalp were evaluated at baseline and at 12 and 24 weeks. Results: After 24 weeks of treatment, hair density and hair thickness were found to have significantly increased (P <.01 and P =0.013, respectively) and sebum secretion of vertex area had decreased significantly (P <.01). Of 49 participants, 73.47% of the participants showed improvement in the overall appearance of the scalp (n = 36). Conclusion: A helmet-like low-level light therapy device can improve the appearance of the hair, with thickening and increase in the density of the hair, and can improve scalp condition by decreasing sebum secretion.

2.
Dermatol Surg ; 45(9): 1155-1162, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-30730346

RESUMO

BACKGROUND: Botulinum toxin (BTX) has been used cosmetically with good clinical efficacy and tolerable safety. OBJECTIVE: This randomized, double-blind, split-face clinical study aimed to investigate the efficacy and safety of intradermal BTX in patients with rosacea. MATERIALS AND METHODS: Twenty-four participants were enrolled and randomly given intradermal injections of BTX and normal saline in both cheeks. Clinician Erythema Assessment (CEA) score, Global Aesthetic Improvement Scale (GAIS) score, skin hydration, transepidermal water loss (TEWL), melanin content, erythema index, elasticity, and sebum secretions were evaluated at baseline and 2, 4, 8, and 12 weeks. RESULTS: On the BTX-treated side, the CEA score significantly decreased and the GAIS score significantly increased. The erythema index decreased at Weeks 4 and 8. Skin elasticity was improved at Weeks 2 and 4 and skin hydration, at Weeks 2, 4, and 8. However, TEWL and sebum secretion did not show significant differences. CONCLUSION: Intradermal BTX injections reduced erythema and rejuvenated the skin effectively and safely in patients with rosacea.


Assuntos
Toxinas Botulínicas Tipo A/administração & dosagem , Eritema/tratamento farmacológico , Eritema/fisiopatologia , Dermatoses Faciais/tratamento farmacológico , Dermatoses Faciais/fisiopatologia , Fármacos Neuromusculares/administração & dosagem , Rosácea/tratamento farmacológico , Rosácea/fisiopatologia , Adulto , Toxinas Botulínicas Tipo A/efeitos adversos , Método Duplo-Cego , Elasticidade , Estética , Feminino , Humanos , Injeções Intradérmicas , Masculino , Pessoa de Meia-Idade , Fármacos Neuromusculares/efeitos adversos , Projetos Piloto , Rejuvenescimento , Sebo/metabolismo , Pele/fisiopatologia
3.
Angiology ; 68(7): 608-613, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27273540

RESUMO

Many recent studies have suggested that psoriasis, a chronic, inflammatory, immune-mediated skin disease, is associated with increased risk of cardiovascular disease (CVD). We aimed to compare arterial stiffness in psoriasis and control patient groups using the cardio-ankle vascular index (CAVI) and to determine whether psoriasis is an independent risk factor for CVD. A total 103 patients with psoriasis and 103 age- and sex-matched controls were enrolled. Compared with controls, the patients showed a higher CAVI ( P = .03), particularly patients older than 40 years. The duration of psoriasis exhibited a positive correlative tendency with CAVI ( P = .066). Moreover, psoriasis is an independent predictor of arterial stiffness after adjusting for other factors ( P = .011). We suggest that psoriasis can be a risk factor for CVD, and older patients with psoriasis of longer disease duration should be monitored carefully for cardiovascular risk.


Assuntos
Índice Tornozelo-Braço , Hipertensão/diagnóstico , Psoríase/diagnóstico , Rigidez Vascular/fisiologia , Fatores Etários , Idoso , Tornozelo/irrigação sanguínea , Índice Tornozelo-Braço/métodos , Pressão Sanguínea/fisiologia , Feminino , Humanos , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Psoríase/terapia , Análise de Onda de Pulso/métodos , Fatores de Risco
4.
Photodermatol Photoimmunol Photomed ; 19(5): 261-4, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14535897

RESUMO

BACKGROUND: Many reports have been released to assess skin types, skin colors and cutaneous sensitivity to broad band UVB or UVA. OBJECTIVE: This study was performed to investigate the usefulness of skin type and skin color as the parameter of narrow band UVB (NBUVB) sensitivity. METHODS: The minimal erythema dose (MED) of 40 psoriasis patients was investigated by irradiating several doses ranging from 200 to 1500 mJ/cm2. Before phototesting, the skin color of buttock was measured with a tristimulus colorimeter. RESULTS: The median and mode value of MED of NBUVB was 950 mJ/cm2. Skin type was well correlated with the MED and there was a significant relationship between the L* value and MED, but not for the a* and b* values. CONCLUSION: The MED value of NBUVB in our study is a basic data to set the phototherapy protocol. Our result showed that skin type and L* value might be useful for predicting the sensitivity to NBUVB irradiation.


Assuntos
Psoríase/patologia , Pigmentação da Pele/efeitos da radiação , Raios Ultravioleta , Nádegas , Relação Dose-Resposta à Radiação , Eritema/etiologia , Humanos , Estatísticas não Paramétricas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA